

ASX Announcement

Melbourne, Australia, 23 November 2023

Annual General Meeting Chair Address

Genetic medicine and exosome-based drug-delivery company Exopharm Limited (ASX: EX1) is pleased to advise provide the Chair Address for today's Annual General Meeting.

By the Chair – this announcement has been authorised for release by the Chair, Mr Mark Davies, on behalf of the Board.

Company and Media Enquiries:

Join our mailing list to receive updates:

<http://exo.ph/ExoMails>

www.exopharm.com

P: +61 (0)3 9111 0026

Ian Dixon
Managing Director

Tel: +61 418 561 907
ian.dixon@exopharm.com

ABOUT EXOPHARM

Exopharm (ASX:EX1) is a leader in advanced manufacturing technologies for exosome-based medicines.

Exosomes can be loaded with a variety of active pharmaceutical ingredients (APIs) and can be targeted to selected cell-types and tissue types, improving the safety-profile of the APIs and providing better treatments. Exosomes can be used to deliver small molecule drugs, mRNA, DNA and other types of APIs.

Exosomes are an alternative means of drug-delivery inside the body, alongside technologies such as lipid nanoparticles (LNP), cell-penetrating peptides, viral vectors and liposomes.

Exopharm's exosome technologies solve important needs for the success of exosome medicines – LEAP manufacturing technology, LOAD API loading technologies and EVPS tropism technologies.

Exosome-based medicines could improve the treatment of many chronic or inherited medical conditions.

Exopharm is making its proprietary technologies available to pharmaceutical and biotechnology companies that want to harness exosome-delivery for their own products.

FORWARD LOOKING STATEMENTS

This announcement contains forward-looking statements which incorporate an element of uncertainty or risk, such as 'intends', 'may', 'could', 'believes', 'estimates', 'targets', 'aims', 'plans' or 'expects'. These statements are based on an evaluation of current corporate estimates, economic and operating conditions, as well as assumptions regarding future events. These events are, as at the date of this announcement, expected to take place, but there cannot be any guarantee that such events will occur as anticipated or at all given that many of the events are outside of Exopharm's control or subject to the success of the Development Program. Furthermore, the Company is subject to several risks as disclosed in the Prospectus dated 23 March 2023.

Annual General Meeting Chair Address

Good afternoon to you.

On behalf of the Exopharm Board of Directors I welcome you to our 2023 Annual General Meeting.

Before proceeding with the formal business of the meeting, I would like to say a few things.

At the 2022 AGM the company had Mr Jason Watson as Chairman and Dr Jennifer King as a Director. Since then, I have taken on the role of Chairman and Mr Clarke Barlow has joined as a Director to replace Dr King.

The company has undergone some significant and essential changes over the past 12 months – most notably building up our cash reserves whilst reducing operating costs dramatically.

We thank our supportive brokers Alto Capital and Canary Capital for their efforts and assistance over the past 12 months.

Over the past months the board of Exopharm have been investigating ways to increase shareholder value. Whilst maximising the significant value of the company's IP position in the exosome field, a strategy has been implemented to seek a transaction that could result in a material change in the company's activities.

As previously communicated, the company sought a trading halt and a temporary suspension from quotation on 2nd October 23 due to a potential transaction. This suspension will continue until we bring a transaction to shareholders and recompile with the ASX Listing rules.

Unfortunately, there is nothing more I can say about the potential transaction at this time, but I can assure you that we are working hard to bring the transaction to shareholders and have the company's shares recommence trading.

On behalf of the Directors, I thank you for your ongoing support and patience. We look forward to sharing more information with you as soon as possible.

Mark Davies
Chair
Exopharm Limited